FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Pat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. DSX
2. GNK
3. INTC
4. SPCX
5. III
6. TTEC
7. DAL
8. AWK
9. BHP
10. MDA

Go back to FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Pat
Merck & Co. (NYSE: MRK) Delayed: 113.87 -1.57 (1.36%)
Previous Close $115.44    52 Week High $65.46 
Open $114.64    52 Week Low $47.97 
Day High $114.94    P/E 77.46 
Day Low $111.57    EPS $1.47 
Volume 29,522,568